GBS (GBS) Competitors $1.25 -0.03 (-1.95%) As of 05/21/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock GBS vs. INO, NVNO, APYX, ICCM, CTSO, MODD, TELA, MDAI, DXR, and NMTCShould you be buying GBS stock or one of its competitors? The main competitors of GBS include Inovio Pharmaceuticals (INO), enVVeno Medical (NVNO), Apyx Medical (APYX), IceCure Medical (ICCM), Cytosorbents (CTSO), Modular Medical (MODD), TELA Bio (TELA), Spectral AI (MDAI), Daxor (DXR), and NeuroOne Medical Technologies (NMTC). These companies are all part of the "surgical & medical instruments" industry. GBS vs. Inovio Pharmaceuticals enVVeno Medical Apyx Medical IceCure Medical Cytosorbents Modular Medical TELA Bio Spectral AI Daxor NeuroOne Medical Technologies GBS (NYSE:GBS) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, community ranking, institutional ownership, profitability, valuation, analyst recommendations and media sentiment. Which has more risk and volatility, GBS or INO? GBS has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Does the media prefer GBS or INO? In the previous week, Inovio Pharmaceuticals had 8 more articles in the media than GBS. MarketBeat recorded 10 mentions for Inovio Pharmaceuticals and 2 mentions for GBS. Inovio Pharmaceuticals' average media sentiment score of 0.18 beat GBS's score of -0.02 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GBS 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Inovio Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is GBS or INO more profitable? GBS's return on equity of -85.64% beat Inovio Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets GBSN/A -85.64% -54.42% Inovio Pharmaceuticals N/A -118.17%-83.47% Does the MarketBeat Community believe in GBS or INO? Inovio Pharmaceuticals received 721 more outperform votes than GBS when rated by MarketBeat users. CompanyUnderperformOutperformGBSN/AN/AInovio PharmaceuticalsOutperform Votes72170.69% Underperform Votes29929.31% Do institutionals & insiders have more ownership in GBS or INO? 2.8% of GBS shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 0.3% of GBS shares are held by company insiders. Comparatively, 2.3% of Inovio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has stronger valuation and earnings, GBS or INO? GBS has higher revenue and earnings than Inovio Pharmaceuticals. GBS is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGBS$440K43.32-$8.31M-$0.56-2.29Inovio Pharmaceuticals$283.10K256.50-$135.12M-$3.19-0.62 Do analysts prefer GBS or INO? Inovio Pharmaceuticals has a consensus target price of $9.75, suggesting a potential upside of 392.42%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than GBS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GBS 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Inovio Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryInovio Pharmaceuticals beats GBS on 11 of the 16 factors compared between the two stocks. Get GBS News Delivered to You Automatically Sign up to receive the latest news and ratings for GBS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GBS vs. The Competition Export to ExcelMetricGBSSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$19.06M$4.50B$5.38B$19.41BDividend YieldN/A43.63%5.21%3.83%P/E Ratio-2.2929.4326.7634.23Price / Sales43.3267.72389.7134.85Price / CashN/A51.0838.2517.51Price / Book2.916.236.784.69Net Income-$8.31M$68.16M$3.23B$1.02B7 Day Performance-0.39%-0.19%1.51%-1.74%1 Month Performance5.79%19.19%10.03%7.46%1 Year Performance-44.59%21.47%16.65%3.96% GBS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GBSGBSN/A$1.26-2.0%N/A-47.8%$18.69M$440,000.00-2.247INOInovio Pharmaceuticals3.6533 of 5 stars$1.92-1.0%$12.20+535.4%-82.0%$70.41M$217,756.00-0.48320NVNOenVVeno Medical0.7554 of 5 stars$3.83+6.1%N/A-29.5%$67.16MN/A-2.9719APYXApyx Medical0.7913 of 5 stars$1.58+43.0%N/A-7.5%$59.72M$48.10M-1.90270Gap DownHigh Trading VolumeICCMIceCure Medical2.0951 of 5 stars$1.04+6.9%$2.50+141.2%-5.5%$57.53M$3.29M-3.5760News CoveragePositive NewsUpcoming EarningsGap UpCTSOCytosorbents2.0349 of 5 stars$0.870.0%$4.67+436.4%-7.4%$54.47M$35.59M-2.42220News CoverageAnalyst ForecastAnalyst RevisionMODDModular Medical0.8811 of 5 stars$0.99-3.3%N/A-48.8%$40.09MN/A-1.8620News CoverageTELATELA Bio1.8515 of 5 stars$0.98-3.0%$7.25+639.8%-77.3%$38.76M$69.30M-0.58120News CoverageMDAISpectral AI3.0457 of 5 stars$1.42+4.4%$4.75+234.5%-21.6%$35.95M$29.58M-2.1883Analyst UpgradeAnalyst RevisionDXRDaxor3.7982 of 5 stars$7.20-0.8%$25.00+247.2%-19.8%$34.83M$2.13M0.0037Gap UpNMTCNeuroOne Medical Technologies1.741 of 5 stars$0.64+3.4%$1.45+125.2%-42.2%$30.52M$5.75M-2.4820Gap UpHigh Trading Volume Related Companies and Tools Related Companies Inovio Pharmaceuticals Alternatives enVVeno Medical Alternatives Apyx Medical Alternatives IceCure Medical Alternatives Cytosorbents Alternatives Modular Medical Alternatives TELA Bio Alternatives Spectral AI Alternatives Daxor Alternatives NeuroOne Medical Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:GBS) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GBS Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GBS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GBS Stock Free GBS Stock Alerts